JP4865868B2 - 悪性中皮種の治療方法 - Google Patents

悪性中皮種の治療方法 Download PDF

Info

Publication number
JP4865868B2
JP4865868B2 JP2009539559A JP2009539559A JP4865868B2 JP 4865868 B2 JP4865868 B2 JP 4865868B2 JP 2009539559 A JP2009539559 A JP 2009539559A JP 2009539559 A JP2009539559 A JP 2009539559A JP 4865868 B2 JP4865868 B2 JP 4865868B2
Authority
JP
Japan
Prior art keywords
antibody
cells
amino acid
seq
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009539559A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010521418A5 (cg-RX-API-DMAC7.html
JP2010521418A (ja
Inventor
幾夫 森本
圭 大沼
輝生 稲元
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tokyo NUC
Original Assignee
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tokyo NUC filed Critical University of Tokyo NUC
Publication of JP2010521418A publication Critical patent/JP2010521418A/ja
Publication of JP2010521418A5 publication Critical patent/JP2010521418A5/ja
Application granted granted Critical
Publication of JP4865868B2 publication Critical patent/JP4865868B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2009539559A 2007-03-14 2008-03-14 悪性中皮種の治療方法 Active JP4865868B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89478607P 2007-03-14 2007-03-14
US60/894,786 2007-03-14
PCT/JP2008/055344 WO2008114876A1 (en) 2007-03-14 2008-03-14 A method of treating malignant mesothelioma

Publications (3)

Publication Number Publication Date
JP2010521418A JP2010521418A (ja) 2010-06-24
JP2010521418A5 JP2010521418A5 (cg-RX-API-DMAC7.html) 2011-03-03
JP4865868B2 true JP4865868B2 (ja) 2012-02-01

Family

ID=39765975

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009539559A Active JP4865868B2 (ja) 2007-03-14 2008-03-14 悪性中皮種の治療方法

Country Status (5)

Country Link
US (2) US20100135993A1 (cg-RX-API-DMAC7.html)
EP (1) EP2131863A4 (cg-RX-API-DMAC7.html)
JP (1) JP4865868B2 (cg-RX-API-DMAC7.html)
CA (1) CA2680368A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008114876A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010099918A1 (en) * 2009-03-06 2010-09-10 Klaus Tschira Stiftung Ggmbh Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient
WO2012024519A2 (en) * 2010-08-18 2012-02-23 Theresa Deisher Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
JP2015030666A (ja) 2013-07-31 2015-02-16 学校法人順天堂 抗ヒトｃｄ２６モノクローナル抗体又はその抗原結合性断片
RU2020142534A (ru) * 2015-09-11 2021-02-01 И' с АК Ко., Лтд. Композиция для лечения рака, объединяющая анти-cd26 антитело и другое противораковое средство
US10282369B2 (en) * 2017-03-08 2019-05-07 Centri Technology, Inc. Fast indexing and searching of encoded documents
JP7064203B2 (ja) * 2018-03-16 2022-05-10 学校法人順天堂 抗ヒトｃｄ２６モノクローナル抗体
WO2022066847A1 (en) * 2020-09-24 2022-03-31 Alnylam Pharmaceuticals, Inc. Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
KR20240007230A (ko) 2021-05-13 2024-01-16 아디에네 에스.에이. 피부근염을 치료하는 방법
MX2023012633A (es) * 2021-05-13 2023-11-09 Adienne S A Metodos de tratamiento de la enfermedad de injerto contra hospedero.
JP2022184105A (ja) * 2021-05-31 2022-12-13 ワイズ・エー・シー株式会社 抗ｃｄ２６抗体と免疫チェックポイント阻害剤との併用療法
CN116023491A (zh) * 2021-10-25 2023-04-28 江苏众红生物工程创药研究院有限公司 抗cd26抗体及其应用
CN116549629A (zh) * 2022-01-30 2023-08-08 江苏众红生物工程创药研究院有限公司 Cd45作为生物标志物在筛查cd26抗体或其衍生物治疗肿瘤有效性和精准性中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004533449A (ja) * 2001-05-11 2004-11-04 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム Ｃｄ２６を発現している細胞に関連する疾患の治療としての抗ｃｄ２６モノクローナル抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1395274A2 (en) * 2001-05-22 2004-03-10 Duke University Compositions and methods for inhibiting metastasis
RU2486204C2 (ru) * 2005-07-22 2013-06-27 Уай'З Терапьютикс Ко., Лтд. Антитела против сd26 и способы их применения

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004533449A (ja) * 2001-05-11 2004-11-04 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム Ｃｄ２６を発現している細胞に関連する疾患の治療としての抗ｃｄ２６モノクローナル抗体

Also Published As

Publication number Publication date
CA2680368A1 (en) 2008-09-25
WO2008114876A1 (en) 2008-09-25
EP2131863A4 (en) 2012-07-11
US20140004103A1 (en) 2014-01-02
EP2131863A1 (en) 2009-12-16
US20100135993A1 (en) 2010-06-03
JP2010521418A (ja) 2010-06-24
US8771688B2 (en) 2014-07-08

Similar Documents

Publication Publication Date Title
JP4865868B2 (ja) 悪性中皮種の治療方法
JP4464450B2 (ja) インスリン様増殖因子ｉ受容体に対する抗体およびその使用
CN109071666B (zh) 人脊髓灰质炎病毒受体(pvr)特异性抗体
RU2571224C2 (ru) Гуманизированные антитела против axl
CN107207593B (zh) 抗pd-1抗体及其使用方法
DK2220121T3 (en) AXL antibodies
JP4997239B2 (ja) 抗ｃｄ２６抗体およびその使用方法
JP5808052B2 (ja) Ｅｇｆファミリーリガンドのアンタゴニストを成分とする医薬組成物
JP2024012382A (ja) Ｃｄ７０に特異的な抗体およびその使用
UA126905C2 (uk) Антитіло до pd-l1 та його застосування
CN112279918A (zh) Cd73抗体及其用途
US10806787B2 (en) Anticancer agents or antimetastatic agents using FSTL1 and combination drug thereof
KR101521863B1 (ko) 암치료에서의 항-ｃｄ151 항체의 사용
KR20100014405A (ko) 암치료용 모노클로날 항체
US20240158517A1 (en) Anti-human cxcr5 antibody and uses thereof
HK40005495B (en) Anti-cd73 antibodies and uses thereof
HK40005495A (en) Anti-cd73 antibodies and uses thereof
HK1244492B (zh) 抗pd-1抗体及其使用方法
HK1132904B (en) Use of an anti-cd151 antibody in the treatment of cancer
HK1151973A (en) Antibodies against a cancer-associated epitope of variant nfkbib and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110111

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20110111

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20110207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110506

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110506

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110628

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20110819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110822

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111101

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111110

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141118

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4865868

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250